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The beta-lactam antibiotics constitute the most
important family of antimicrobial agents, in terms of
both the large number of compounds available and
the prescription volume. Until recently, beta-lac-
tams were not considered strong candidates for ther-
apeutic drug monitoring (TDM), as they are
assumed to have a wide therapeutic index and the
most frequent adverse effects involve non-dose-
related allergic reactions. But concepts are chang-
ing, and several studies demonstrate the advantage
of TDM for these antibiotics (1).
Clinicians and pharmacologists agree that cer-
tain adverse events like encephalopathy, seizure,
and pseudolithiasis occur when their doses are
excessive. Various infectious diseases, e.g., endo-
carditis, meningitis, and osteomyelitis require
administration of high-dose antibiotics via intermit-
tent or continuous infusion (2). Knowledge of the
antibiotic plasma concentrations combined with
bacterial susceptibility evaluated in terms of the
minimum inhibitory concentration (MIC) would
enable treatment efficacy to be optimized by limit-
ing the risk of dose related adverse effects and
avoiding suboptimal concentrations (3). 
Cefuroxime sodium (CFU) is a semisynthetic,
broad-spectrum, second-generation cephalosporin
antibiotic agent for parenteral administration. It is
resistant to destruction by beta-lactamases produced
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Abstract: A rapid and inexpensive high-performance liquid chromatography method with UV detection for
determination of cefuroxime (CFU) in small human serum samples was developed and validated. In this
method, serum samples were spiked with an internal standard and proteins were precipitated by 0.4 M per-
chloric acid. Separation was carried out on an RP-18 column with a mobile phase composed of 20 mM potas-
sium dihydrogen phosphate buffer and methanol (85 : 15; v/v), pH 4.5. In order to assess the usefulness of
newly developed method in CFU dosage design, CFU concentrations in serum from 6 patients with lower res-
piratory tract infections ranging in age from 43 to 91 years were determined. The antibiotic was administered
intravenously at a dose of 1500 mg every 8 hours for 10-14 days. Pharmacokinetic analysis and simulations
were performed using Phoenix WinNonlin. Dosage optimization was based on pharmacokinetic-pharmacody-
namic (PK/PD) indices. The lower limit of quantification of the assay was 0.25 µg/mL and the calibration curve
was linear at the concentration range from 0.25 to 300 µg/mL. The method was characterized by an excellent
precision (≤ 6.4%) and accuracy (≤ 9.0%). Recoveries ranged from 92% to 96%. CFU in serum samples was
stable when stored at -30OC for at least 10 days, at room temperature (+22OC) for up to 6 h, and during three
freezeñthaw cycles, when stored at -30OC and thawed to room temperature. Pharmacokinetic analysis showed
significant differences in pharmacokinetic parameters of CFU in the studied patients: volume of distribution
was from 8.9 to 20.6 L, terminal elimination half-life from 1.3 to 5.3 h, and total body clearance from 31 to 232
mL/min. In the elderly patients studied dosage optimization was required. These results suggest that our sim-
ple and rapid HPLC method may be useful to monitor serum CFU concentrations in patients on standard
dosages and to support determination of CFU dosage regimens based on the PK/PD indices.
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by staphylococci and most Gram-negative aerobic
bacteria and is active against many bacteria resistant
to cephalothin. CFU is the most active of the
cephalosporins against gonococci and Haemophilus
influenzae, particularly against beta-lactamase pro-
ducing strains. Given by intravenous or intramuscu-
lar injection CFU is effective against a wide variety
of infections caused by Gram-positive or Gram-neg-
ative aerobes, but has no effect against infections
caused by Pseudomonas aeruginosa or Bacteroides
fragilis. In addition, it is of value in the treatment of
respiratory infections due to Haemophilus influen-
zae and Streptocococcus pneumoniae and is useful
against cephalosporin-resistant Klebsiella spp. and
Enterobacter infections. It is an alternative to
spectinomycin for the treatment of beta-lactamase
producing Neisseria gonorrhoeae infections.
Moreover, this antibiotic is generally well tolerated
and does not appear to be nephrotoxic when given
alone at usual dosages. CFU has been widely used
for the treatment of patients having infections of soft
tissues, respiratory tract, urinary tract, genital tract,
central nervous system, and bone and joint tissues
(4, 5).
Pharmacokinetics of CFU has been examined
both in healthy subjects and in patients with infec-
tions or renal failure. The volume of distribution of
this drug ranges from 12 to 18 liters and, at thera-
peutic concentrations, 30% of this drug is bound to
plasma proteins. Renal excretion accounts for 96%,
whereas the biological half-life is from 1.4 to 1.8 h
in normal subjects and increases to approximately
20 h in anuric patients (6-10) The pharmacokinetic
parameters are highly variable between individuals,
therefore determination of CFU serum concentra-
tions is necessary to ensure the effectiveness of
treatment. Inter-patient differences in pharmacoki-
netics and the frequently associated toxicity of CFU
after prolonged use makes therapeutic drug monitor-
ing strongly recommended. Therefore, a simple,
fast, inexpensive, and reliable analytical method for
the determination of CFU in body fluids is needed.
Increased knowledge of the pharmacokinetic/phar-
macodynamic (PK/PD) properties of antibiotics is
useful for optimising dosage regimens. The bacteri-
cidal action of CFU, similarly to all β-lactam antibi-
otics depends on the time at which blood concentra-
tions will be greater than the MIC of bacteria caus-
ing infection (TC > MIC) (11-13). These drugs have
relatively slow bactericidal action and no or short
post-antibiotic effects (PAEs) (14, 15). Experimen-
tal studies have shown that for β-lactam antibiotics
this time value in moderate infections should be at
least 70% and in severe infections 100% of the dos-
ing interval (16-18). Literature data indicate signif-
icant changes in the processes of elimination of
CFU observed especially in geriatric patients that
manifest mainly by decreased clearance of the
drug. As a result, with the usual dosage of CFU in
this group of patients significant changes in the
values of the parameter TC > MIC are observed
that affect the effectiveness of treatment and create
a need for individualized dosing of the drug, e.g.,
based on the measured concentration of this drug in
blood (16-20).
The analytical method used to monitor the con-
centration of the drug in biological material should
have an excellent accuracy, sensitivity, precision,
and selectivity. Moreover, it should be fast, inex-
pensive, require small sample volumes of biological
material as well as sample preparation time should
be minimized (21).
Up to date, several analytical methods for mon-
itoring of plasma CFU levels have been reported.
Most of these assays were based on the use of
microbiological techniques (8, 22) or high perform-
ance liquid chromatography (HPLC) coupled with
UV-detection (23-28). Among the currently avail-
able bio-analytical techniques, liquid chromatogra-
phy coupled with mass spectrometry (LCñMS) and
tandem mass spectrometry (LCñMS/MS) has been
emerged as the preeminent analytical tool for quan-
tification of small molecular weight drugs in biolog-
ical matrix (29-32). Different extraction procedures
including solid phase extraction (23, 25, 29, 30),
ultrafiltration (34), protein precipitation combined
with back-extraction (33) or protein precipitation
followed by supernatant evaporation (24, 28) have
been used for cleanup and enrichment of plasma
samples. However, all of these methods have weak-
nesses, e.g., although the absolute recoveries
obtained with solid phase extraction were reason-
ably good, the main problems encountered with this
procedure was the high plasma volume of at least
0.5 to 1 mL required, multi-step purification and
evaporation as well as a relatively high cost (23, 25,
29). Ultrafiltration is another effective extraction
method providing good recoveries and the measure
of the free fraction of the drug but it is quite expen-
sive (34). The mass spectrometric detection had the
advantage of being a fast, specific, and sensitive
technique for the simultaneous determination of
many β-lactams (29-32) but it could not be imple-
mented in all laboratories due to the high cost of
analyses and the special equipment required. It is
substantially more sensitive than known HPLC-UV
methods as it allows for CFU quantification in the
range 0.025-50.0 µg/mL using only 100 µL of plas-
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ma (32). Still, much less expensive HPLC-UV
methods enable sufficient for the pharmacokinetic
studies of CFU administered at standard doses sen-
sitivity, i.e., lower limit of quantification (LLOQ =
0.1- 0.2 µg/mL) (24-26).
An analytical method suitable for TDM must
be fast and robust, and it should provide results to
the clinical ward within a few hours. Most of the
reported CFU assays were based on time-consuming
low-throughput sample preparation steps. They
include laborious procedures, e.g., multiple centrifu-
gation steps (24, 28) or evaporation-to-dryness pro-
cedures (23, 25, 29) that significantly lengthen the
total analysis time. Therefore, there is a need to
develop a fast, simple, inexpensive, and reliable
analytical method for CFU determination to be used
for TDM purposes.
The aim of this work was to develop a simple,
precise, rapid, and low-cost HPLC method for deter-
mination of CFU in human serum and to validate
this method according to the US Food and Drug
Administration and European Medicines Agency
guidelines (35, 36). In addition, this method was
used to determine CFU serum levels in patients hos-
pitalized in the Department of Internal Medicine and
Gerontology, Jagiellonian University Medical
College due to bacterial infections in order to adjust
the dosage of this drug so as to optimize the time
above MIC and minimize the risk of dose related
adverse effects.
MATERIALS AND METHODS
Chemicals and reagents
Cefuroxime sodium salt and cefotaxime sodi-
um salt (internal standard, IS) were supplied by
Sigma-Aldrich (Steinheim, Germany). Other drugs
used in this study included ciprofloxacin hydrochlo-
ride, gentamicin sulfate, amikacin sulfate, acetamin-
ophen, amiodarone, digoxin, disopyramide, ampho-
tericin B, flunitrazepam, ertapenem, propranolol,
salicylic acid, and theophylline and were also from
Sigma-Aldrich, Germany. Methanol for chromatog-
raphy LiChrosolv® was obtained from Merck
(Darmstadt, Germany). Analytical-grade concen-
trated orthophosphoric acid (85%) and potassium
dihydrogen phosphate were purchased from Fluka
(Germany). Drug free human serum was received
from a healthy volunteer.
Apparatus and chromatographic conditions
The HPLC/UV system (Thermo Separation
Products, San Jose, CA, USA) consisted of a P100
pump, a Rheodyne injector 7125 (Rheodyne, Cotati,
CA, USA) with a 20 µL loop, a UV100 variable-
wavelenghth UV/VIS detector, and a SP4400
(ChromJet) integrator. The analysis was performed
on a LiChrospher 100RP-18 (125 mm x 4 mm i.d., 5
µm particle size) column coupled with a
LiChroCARTÆ guard column (4.0 ◊ 4.0 mm, 5 µm)
(Merck, Darmstadt, Germany). The mobile phase
consisted of a mixture of methanol : 20 mM potassi-
um dihydrogen phosphate buffer (15 : 85; v/v). It
was prepared with 2.7218 g potassium dihydrogen
phosphate dissolved in 1000 mL of water. The pH
was adjusted to 4.5 with concentrated orthophos-
phoric acid. The mobile phase was prepared daily,
filtered through a 0.45 µm membrane filter
(Supelco, Germany) and degassed before use. CFU
was eluted isocratically at room temperature with a
flow rate of 1.2 mL/min. The UV detection wave-
length for CFU and IS was 275 nm. The sample
injection volume was 20 µL and the chromatograph-
ic run time was 10 min. 
Preparation of solutions
A stock solutions of CFU (2 mg/mL) and IS (1
mg/mL) were prepared by dissolving 21.0865 mg
cefuroxime sodium salt and 10,4830 mg cefotaxime
sodium salt (IS) in 10 mL deionized water and
stored at -30OC. The stock solution was diluted with
water to obtain working solutions of 0.25; 0.5; 5; 25;
50, 10, 200, and 300 µg/mL for serum calibration
samples. 
Quality control (QC) samples were prepared
by adding an appropriate volume of the working
solutions to drug free serum to obtain a final con-
centrations of 0.25, 1, 150, and 300 µg/mL (LOQ ñ
limit of quantification, low, medium, and high QC,
respectively). QC samples were divided into 500 µL
aliquots and stored at -30OC.
Sample preparation
In order to isolate CFU from serum, to 100 µL
of serum samples containing this antobiotic 10 µL of
IS (100 µg/mL) was added. Then, the samples were
vortex-mixed for 10 s and deproteinized with 0.4 M
HClO4 (200 µL). The solution was vortexed for 15 s
and centrifuged for 5 min at 12 000 rpm at +4OC
(EBA 12R, Hettich, Germany). Finally, 20 µL of
clear supernatant of each sample was injected into
the HPLC system. All samples were prepared in
duplicate.
Validation
The method was validated according to the
procedures and acceptance criteria recommended
for bioanalytical method validation for pharmacoki-
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netic studies (35, 36). The method was then validat-
ed regarding selectivity, specificity, linearity, accu-
racy and precision, limit of detection, limit of quan-
tification, recovery, and stability.
Selectivity and specificity
The selectivity were measured by analyzing six
different drug-free serum samples applying the
developed analytical procedure. The retention times
of endogenous compounds were compared with that
obtained for CFU.
Specificity was assessed using different serum
samples containing 10 drugs frequently prescribed
in the elderly patients that were analyzed to investi-
gate potential interferences. The drugs were aceta-
minophen, amiodarone, digoxin, disopyramide, flu-
nitrazepam, amphotericin B, ertapenem, propra-
nolol, salicylic acid, and theophylline. Due to the
fact that several patients received CFU in combina-
tion with other anti-infective drugs, such as gentam-
icin, amikacin, and ciprofloxacin, potential inter-
ferences of CFU with these drugs were also investi-
gated. 
Linearity
Linearity study was performed by analysis of
standards (from 0.25 to 300 µg/mL) in sixplicate.
Calculations were made using the ratio of the
observed peak areas of CFU and IS. Linear regres-
sion analysis of the calibration data was performed
using the equation: y = ax + b, where y is the peak
area ratio, x is serum concentration of CFU, and a
and b are two constants. Unknown concentrations
were computed from the linear regression equation
of the peak area ratio against CFU concentrations.
Slopes, intercepts, and coefficient determination
(R2) were obtained by the linear regression analysis. 
Precision and accuracy 
Accuracy was determined by the mean of the
measured QC concentration relative to the theoreti-
cal value and was reported in percentage. Precision
was defined as the ratio of the standard deviation of
the observed QC concentration to the mean
observed QC concentration. The intra-day and the
inter-day precision and accuracy for serum QCs
were calculated for three concentrations (low ñ 1
µg/mL, medium ñ 150 µg/mL, and high ñ 300
µg/mL) analyzed six times on the same day, while
inter-day study was performed by assaying the same
three QC concentrations once-a-day on 5 separate
days. Precision was reported as the coefficient of
variation (CV) and calculated according to the equa-
tion: (S.D./mean)◊100 and accuracy as the bias
(RSD) and it was calculated as follows: [(measured
concentration - theoretical concentration)/(theoreti-
cal concentration)] ◊ 100. Acceptance criteria for
accuracy and precision were: bias within ±15%
(except ± 20 % for the LOQ QC) and CV lower than
15% (except 20 % for the LOQ QC).
Limit of detection and limit of quantitation
The limit of detection (LOD) was determined
based on the signal-to-noise ratio of 4 : 1. It was
experimentally determined by analyzing serum sam-
ples spiked with CFU at 0.1, 0.25, 0.5, 1.0, 2.0, and
2.5 µg/mL concentrations. The lower LOQ was cho-
sen as the concentration which provided measure-
ments with a precision and accuracy within the rec-
ommended ± 20% from their nominal values (36).
Recovery
CFU recovery was quantified at concentration
levels corresponding to the lowest (1 µg/mL), medi-
um (150 µg/mL), and highest (300 µg/mL) standard
concentrations analyzed in sixplicate. Absolute
recovery of CFU from serum was estimated by the
peak area integrated for CFU in serum assayed
according to the procedure described above versus
the peak area integrated for CFU after direct injec-
tion of the same concentration in purified water
expressed as percentage.
Cefuroxime stability 
Stability of CFU in human serum was evaluat-
ed by assaying samples that had been stored at +22,
+4, and -30OC for 10 days. Low (1 µg/mL), medium
(150 µg/mL), and high (300 µg/mL) QC concentra-
tions were prepared in triplicate from a freshly made
stock solution in human serum and were investigat-
ed under different conditions. Bench-top stability of
QC samples was assessed after exposure of the
serum samples to room temperature (+22∞C) for 6 h,
which exceeds the residence time of the sample pro-
cessing procedures. The freeze-thaw stability was
performed after freezing (at -30OC) and thawing the
QC samples at room temperature for three cycles. In
addition, the stability of CFU and IS stock solutions
were evaluated by testing their validity at room tem-
perature. The stock solutions studied were freshly
prepared and their aliquots were kept at room tem-
perature up to 6 h (stability samples). After this peri-
od of time, they were diluted with water to the con-
centration of 1, 150, and 300 µg/mL and the mean
peak areas were compared with those of freshly pre-
pared stock solutions. All data were compared with
the results obtained from freshly prepared and ana-
lyzed QC samples using the formula: [stability (%)
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= (stored QC concentration/freshly prepared QC
concentration)∑100]. The samples were considered
stable in human serum at each concentration if the
deviation from the mean calculated concentration of
stability quality control samples was within ± 10%
(35, 36).
Patients
The developed method was applied to the
quantitative analysis of CFU in serum of 6 patients
(4 females, 2 men) ranging in age from 41 to 91
years with lower respiratory tract infections, hospi-
talized in the Department of Internal Medicine and
Gerontology, Jagiellonian University Medical
College. Patients were treated with CFU (Zinacef,
GlaxoSmithKline, UK) administered intravenously
at a dose of 1500 mg every 8 h for 10-14 days. All
CFU treated patients were diagnosed with bron-
chopneumonia or lobar pneumonia and underwent
routine examinations. Moreover, X-ray of the chest
and the basic laboratory tests were performed.
Determinations were made by standardized bio-
chemical methods. 
Serum creatinine was used to calculate creati-
nine clearance (CLcr) according to equation:
CLcr = {Fx [140 ñ age (years)] ∑ weight (kg)}/
Scr (µM/L) [mL/min]                   (1)
where Fx is 1.04 for women and 1.23 for men, and
Scr is serum creatinine concentration (37). 
On the basis of the interview which was carried
out in the entire group of patients, it was found that
2 of them had type 2 diabetes. The demographic data
of the study patients are presented in Table 1.
Material for microbiological testing was isolat-
ed from blood cultures. Microbiological examina-
tion included assessment and identification of the
isolated pathogen and determination of antibiotic
susceptibility (MIC). The sensitivity to CFU was
measured by E-test kits (AB Biodisk, Solna,
Sweden) in accordance with the package insert.
MICs of CFU for isolated pathogens were deter-
mined by the clinical microbiology laboratory at the
institution where the study was performed. The
results of the microbiological tests are shown in
Table 6.
Blood samples were collected from the fore-
arm vein at steady state (3-4 days of treatment)
before the next dose, just after administration, fol-
lowed by 0.5, 1.5, 5.5, and 7 h after dosing. Blood
was allowed to clot for 15-20 min and centrifuged at
1000 × g for 10 min. Serum samples were immedi-
ately transported on ice to the laboratory and stored
at -30OC until analysis. In the day of analysis they
were thawed and followed the procedure described
above. The study protocol was approved by the
Bioethics Committee of the Jagiellonian University.
Pharmacokinetic analysis and simulations
The pharmacokinetic parameters of CFU were
estimated by both model-independent and model-
dependent methods using Phoenix WinNonlin v. 6.3
(Pharsight Corp., Mountain View, CA, USA). In the
non-compartmental approach, the terminal slope (lz)
was calculated from the terminal portion of the log
concentration vs. time profile by linear regression
and the terminal elimination half-life (t0.5λz) was cal-
culated as 0.693/λz. The area under serum concen-
trationñtime curve (AUC0ñτ) and the area under the
first moment of serum concentrationñtime curve
(AUMC0ñτ) over one dosing interval were calculated
using the linear trapezoidal rule. The mean resi-
dence time (MRT0ñτ) was calculated as AUMC0ñτ
/AUC0ñτ, the total body clearance (CLT) was calcu-
lated according to the equation: CLT =dose/AUC0ñτ,
and the steady-state volume of distribution (Vdss)
was calculated as MRTiv◊CLT. The two-compart-
ment pharmacokinetic model was used to estimate
pharmacokinetic parameters of CFU that were sub-
sequently used to predict steady-state concentration-
time profiles for each patient at different dosing
schemes. Goodness of fit was evaluated by the stan-
dard procedures (38). Simulated concentrations
Table 1. Characteristics of patients with lower respiratory tract infections treated with CFU.
Patient Age Wt Height Sex Serum creatinine CLcr
no. (yr) (kg) (cm) (F - female, M - male) (µM/L) (mL/min)
1. 43 52 164 F 72 73
2. 43 131 178 M 89 176
3. 69 70 164 F 121 43
4. 66 71 178 M 106 49
5. 86 50 158 F 92 30.5
6. 91 58 166 F 77 37
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were corrected for 33% protein binding of CFU
(39).
Determination of predictive PK/PD index
The percentage of time that unbound CFU con-
centrations exceeded the MIC (% f TC > MIC) was
determined according to the equation: 
% fTC > MIC = ln[Dose∑f/(Vd ∑ MIC)] ∑ 
[t0.5/0.693] ∑ [100/DI]                    (2)
where, f is the fraction of unbound drug, Vd is vol-
ume of distribution (L), t0.5 is elimination half-life
(h), DI is dosing interval (h), and MIC is the lowest
concentration of an antibiotic that completely
inhibits the growth of a microorganism (µg/mL). 
The percentage of time during which free CFU
concentrations were higher than MIC (% fTC >
MIC) was calculated for each patient. The pharma-
codynamic goal for CFU was the target %fTC >
MIC of unbound drug equal to at least 70% of the
dosing interval. All calculations were performed by
Microsoft ExcelÆ program.
Figure 1. Chromatograms of control serum (A), serum containing CFU at a concentration of 200 µg/mL and IS at a concentration of 100
µg/mL (B), serum of a patient treated with CFU at a dose of 1500 mg iv every 8 hours taken just before the next dose (C), and serum of a
patient treated with CFU at a dose of 1500 mg iv every 8 hours taken immediately after administration of the next dose (D). Peaks: 1 =
CFU, 2 = IS
Table 2. Within- and between-day precision (CV) and accuracy (RSD) of the HPLC method for the determination of CFU in human serum.
Theoretical 
concentration of CFU Intra-day (n = 6) Inter-day (n = 6)
[µg/mL]
Mean (  SD) measured CV RSD Mean (  SD) measured CV RSD 
concentration [µg/mL] [%] [%] concentration [µg/mL] [%] [%]
1 0.93 ± 0.039 4.19 -7.00 0.91   0.058 6.37 -9.00
150 148.38 ± 2.06 1.39 -1.08 148.25   2.99 2.01 -1.17
300 301.53 ± 3.30 1.09 0.51 302.83   7.13 2.35 0.94
Table 3. Mean ± SD recoveries (%) of CFU (n = 6). 
Concentration of CFU 1 µg/mL 150 µg/mL 300 µg/mL
Mean ± SD 94.70 ± 6.70 92.37 ± 2.03 96.04 ± 7.92
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RESULTS
Method validation
Representative chromatograms of blank serum,
serum sample spiked with 200 µg/mL of CFU, and
serum samples from patients treated with CFU are
shown in Figure 1. The average retention times were
6.15 ± 0.36 min and 8.63 ± 0.29 min for CFU and
IS, respectively.
The method was found to be selective as no
interference was found with endogenous com-
pounds in five different blank sera. In addition, the
method was specific as no interference was found
with other drugs (acetaminophen, amiodarone,
digoxin, disopyramide, flunitrazepam, amphotericin
B, ertapenem, propranolol, salicylic acid, and theo-
phylline), including other anti-infective agents (gen-
tamicin, amikacin, and ciprofloxacin) that may be
taken concomitantly in this patient population. 
The calibration curves for CFU were linear in
the concentration range evaluated (0.25ñ300 µg/mL
human serum). The representative linear equation
was y = 0.0078x + 0.00048, with a coefficient deter-
mination (R2  = 0.9993 - 0.9997) highly significant
for the method.
The LOD of the assay was 0.1 µg/mL, whereas
LOQ was 0.25 µg/mL with the relative error not
exceeding 10%. Acceptance criteria for accuracy
and precision were met in all cases. Intra-day accu-
racy ranged from -7.0 to 0.51% and inter-day accu-
racy ranged from -9.00 to 0.94%. Intra- and inter-
day precisions were less than 4.2 and 6.4%, respec-
tively (Table 2).
The mean recovery of CFU calculated for three
standard concentrations was 94.37 ± 1.9% (Table 3).
The mean recovery of IS was 91.33 ± 6.1%.
The stability of CFU in human serum was
inspected during all the storage steps (i.e., at +22OC,
+4OC, and -30OC). The stability of CFU in human
serum was satisfactory up to 240 h of storage at -30OC
and up to 72 h at +4OC, whereas an important degra-
dation occurred after 24 h of storage at room temper-
ature (22OC). The results of long-term stability studies
for the concentration of 150 µg/mL as an example are
presented in Figure 2. The stability results summa-
rized in Table 4 showed that CFU spiked into human
serum was stable for at least 6 h at room temperature,
and during three freezeñthaw cycles, when stored at
around -30OC and thawed to room temperature. The
stock solution of CFU and IS were also stable at room
temperature for at least 6 h.
To assess the usefulness of the developed
method, serum samples from 6 patients with lower
respiratory tract infections receiving intravenous
dose of 1500 mg CFU every 8 h were analyzed.
Figure 3 illustrates individual profiles of CFU con-
centrations determined at steady state (3-4 day of
treatment) before the next dose, just after drug
administration, followed by sampling at 0.5, 1.5,
5.5, and 7 h after dosing.
Pharmacokinetic parameters of CFU estimated
using non-compartmental analysis by means of
Phoenix WinNonlin v. 6.3 are shown in Table 5.
Table 6 shows the times at which free serum
concentrations of CFU were greater than MIC (f∑TC >
MIC) of the pathogen causing the infection expressed
Figure 2. Long-term stability of CFU at a concentration of 150 µg/mL in human serum at 22OC (room temperature), +4OC, and -30OC (n = 3)
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in percentages of dosing interval (%t) and in hours
and, where necessary, new dosing intervals (DI) were
proposed and corresponding f∑TC > MIC values were
calculated. The calculations were performed for each
patient using Equation 2. Based on the pharmacoki-
netic parameters estimated using a two-compartment
pharmacokinetic model computer simulations were
carried out in order to confirm the appropriateness of
the new dosing intervals presented in Table 6 (last
column). The results of these simulations together
with the MIC values of the bacterial strains isolated
from blood of patients are presented in Figure 4.
DISCUSSION
The knowledge of pharmacokinetics and pharma-
codynamics of an antibiotic is the basis for its dose opti-
mization in order to increase efficacy of therapy and
minimize the risk of side effects. In the case of drugs
with a low therapeutic index (e.g., aminoglycoside
antibiotics) individualization of dosing plays an impor-
tant role due to their toxicity, while in the case of less
toxic drugs (e.g., β-lactam antibiotics) because of possi-
ble underdosing and thus, the danger of an increased
resistance of bacterial strains. The pharmacokinetic and
pharmacodynamic criteria allow predicting the likeli-
hood of a therapeutic effect. Therapeutic drug monitor-
ing is particularly desirable in patients having a large
deviation of pharmacokinetic parameters from the pop-
ulation mean values as a result of pathophysiological
(renal failure, liver, cardiovascular system) or physio-
logical (age, gender, pregnancy) factors (19, 20).
Advancing age may influence the pharmacoki-
netics of antibiotics in several ways. The renal elim-
Figure 3. Individual steady-state CFU serum concentration versus time plots of 6 patients receiving this drug intravenously at a dose of
1500 mg every 8 hours
Table 4. Stability data for CFU in human serum/deionized water under various conditions (n = 4).
Nominal Average measured
concentration concentration SD
CV Remaining
[µg/mL] [µg/mL]
[%] [%] ± SD
Three freeze/thaw 1 0.981 0.012 1.18 98.10 ± 1.15
cycles 150 152.83 2.45 1.60 101.39 ± 1.63
(-30OC) 300 301.47 3.65 1.21 100.49 ± 1.21
Bench-top stability 1 0.989 0.063 6.33 98.99 ± 6.26
for 6 h in human serum 150 142.52 1.83 1.29 95.01 ± 1.22
(22OC) 300 309.36 4.43 1.43 103.12 ± 1.48
Bench-top stability 1 0.977 0.011 1.09 97.69 ± 1.06
for 6 h in deionized water 150 143.31 3.52 2.45 95.54 ± 2.34
(22OC) 300 289.49 3.89 1.34 96.49 ± 1.29
Time (h)
C
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ination of a number of compounds has been shown
to decline in parallel with the age-associated reduc-
tion in renal function. In turn, the evidence of
changes in distribution, metabolism, and biliary
excretion in the elderly is less conclusive. Despite a
number of known age-associated alterations in gas-
trointestinal function, no significant change in the
absolute bioavailability of antibiotics has been
reported (40). Antibiotic treatment of elderly
patients is difficult because of the progressive and
age-related changes that occur in the body of the
patient for example such as: multiple organ dys-
function, an increased body fat, or a reduction in
total body water. Moreover, in parallel with the dis-
Figure 4. Observed (●) and predicted (- -) total serum concentrations of CFU in 6 patients relative to the MIC values of pathogens that
caused infections in these patients. Solid lines represent simulated concentrations of unbound CFU in serum. Simulations were performed
based on the individual pharmacokinetic parameters and dosing intervals proposed in Table 6 (last column)
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Table 5. Individual pharmacokinetic parameters of CFU (1500 mg iv every 8 h) estimated in patients with lower respiratory tract infections
using non-compartmental analysis. 
Patient AUC0-τ MRT0-τ Vdss CLCFU λz t0.5λz
no. [mg ∑ h/mL] [h] [L] [mL/min] [h-1] [h]
1. 174.20 1.439 12.275 142.20 0.551 1.25
2. 106.92 1.482 20.582 231.54 0.491 1.41
3. 217.82 2.715 18.124 111.25 0.286 2.42
4. 235.93 3.363 20.489 101.55 0.238 2.91
5. 765.79 2.854 8.901 19.65 0.131 5.30
6. 759.57 4.962 9.217 30.96 0.176 3.94
Mean 376.705 2.802 14.930 106.192 0.312 2.872
± SD ± 275.931 ± 1.197 ± 4.987 ± 70.952 ± 0.156 ± 1.415
AUC0-τ = area under the serum concentration-time curve of the 8 h dosing interval; MRT0-τ = mean residence time; Vdss = volume of dis-
tribution at steady-state; CL = total body clearance; λz = terminal slope t0.5/λz = terminal half-life.
Table 6. Microbiological data of the patients receiving CFU at a dose of 1500 mg iv every 8 h and calculated PK/PD indices.
Patient no. Bacteria strain
MIC % fTC > fTC > MIC New DI/
[µg/mL] MIC [%τ] [h] %fTC > MIC
1. S. aureus 1 99.32 7.95 -
2. S. pneumoniae 1 98.89 7.91 -
3. M. catarrhalis 1 175.28 14.02 12 h/116.85
4. S. pneumoniae 2 167.95 13.44 12 h/111.97
5. H. influenzae 4 319.34 25.55 24 h/106.45
6. S. aureus 2 284.17 22.73 24 h/94.72
DI - dosing interval
comfort from aging, chronic diseases, such as car-
diovascular disease, osteoarthritis, and diabetes are
more common in this population, which explains
why most of the elderly are treated with polythera-
py. All of these factors can significantly affect the
pharmacokinetics and therapeutic efficacy of
antimicrobial drugs and create the need for individ-
ualization of dosage as well as continuous monitor-
ing of therapeutic effects in the elderly patients (41).
The most crucial step in optimization of drug
therapy is the development of a suitable analytical
method that allows for precise and accurate determi-
nation of drug concentration in biological fluids.
Literature data indicate that among methods avail-
able for the determination of CFU in serum, HPLC
technique is the most frequently used (24-28). 
The aim of the study was to develop a simple,
rapid, and low-cost assay for determination of CFU
in human serum using HPLC method coupled with
ultraviolet detection and to validate this method
according to the FDA and EMA guidelines (35, 36).
This method was applied for determination of CFU
serum concentrations in infected patients in order to
obtain pharmacokinetic profiles of this antibiotic at
steady state. Furthermore, this method can be
applied in the clinical field to adjust the doses of
CFU based on the PK/PD indices. The advantage of
our method over those previously published lies in
the simple preparation of the samples. When devel-
oping the method, the use of acetonitrile, methanol,
and 0.4 M perchloric acid for protein precipitation
was evaluated. The best recoveries were obtained
using perchloric acid (data not shown). Compared to
other procedures reported in the literature, our
method is cost-effective (23, 25, 29, 30). The rela-
tively low price of a single column and reagents are
important for pharmacokinetic and clinical laborato-
ry investigations. In the developed analytical
method only 100 µL of serum was used. Small vol-
ume of a sample is very important for the pharma-
cokinetic studies, particularly in children and geri-
atric and critically ill patients. The methods present-
ed in literature usually require 0.5-1 mL of serum
(23-25). In addition, in our method a total run time
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is < 10 min. The retention times of CFU in
serum/plasma described by other authors were 10 or
20 min (23, 24). 
The blank serum showed no interference of
endogenous substances with CFU and IS.
Potentially co-administered drugs had retention
times different than CFU or were not extracted and
detected when using our method. This points to the
possibility of monitoring the concentrations of CFU
using the developed analytical method in patients
treated with combination of CFU and other drugs
concomitantly used especially in the elderly
patients. Calibration range was based on CFU con-
centrations observed in human serum at steady-state
when CFU was administered at a dose of 1500 mg iv
every 8 h. The complete recovery of CFU from
serum (approximately 95%) reported for this
method provides evidence that this simple extraction
procedure is sufficient for therapeutic drug monitor-
ing. Moreover, the developed method was charac-
terized by good inter- and intra-day accuracy and
precision. The obtained LOQ of 0.25 µg/mL from
only 100 mL of serum samples was sufficient for
clinical applications, as reported minimal concentra-
tions were higher than 0.5 µg/mL at recommended
CFU dosages (24, 29, 34). Moreover, according to
the European Committee on Antimicrobial
Susceptibility Testing (42), clinical breakpoints of
CFU ranging from 0.5 to 8.0 µg/mL are greater than
our LOQ, allowing clinical applications of this
method.
The stabilities of CFU were investigated at
three concentrations of QC samples (low, medium,
and high concentrations) to cover expected condi-
tions during analysis, storage, and processing of all
samples, which include the stability data from vari-
ous conditions like bench-top, freeze/thaw, and
long-term storage. CFU was considered stable in
serum if at least 90% of antibiotic was retained at
the end of the study period (35, 36). Long-term sta-
bility tests showed that concentrations of the CFU in
human serum remained stable at -30OC for at least
240 h (all biases were comprised between -8.7 and
7.8%). No trend towards degradation of CFU was
found in relation to freeze-thaw cycles, as average
stability results ranged from 98.1% (1.2%) to
101.4% (1.6%) in serum. Storing QC samples at
room temperature for 6 h had no influence on CFU
quantification. Mean CFU concentrations ranged
from 95.0% (1.2%) to 103.1% (1.5%) for human
serum. Stock solutions were stable for at least 6 h at
room temperature because no significant degrada-
tion was found between solutions stored at 22OC for
6 h and solutions freshly prepared. Consequently,
blood samples should be transported to the laborato-
ry preferably on ice, immediately centrifuged, and
serum samples may be stored at -30OC for at least
240 h after collection. 
The newly developed method was used for
determination of CFU concentrations in six patients
receiving CFU intravenously at a dose of 1500 mg
every 8 h for 10-14 days. Basic pharmacokinetic
parameters of the drug were calculated using non-
compartmental analysis. The values of volume of
distribution of CFU estimated in the study group
varied and ranged from 8.9 to 20.6 L. These signifi-
cant differences in this parameter could be due to
pathological changes, mainly in the cardiovascular
system and associated diseases, such as type II dia-
betes or hypertension (1, 5, 41). Values of CFU
clearance in the study group was 106.19 ± 70.95
mL/min and in 4 out of 6 patients was almost 2-3
times lower than those in the average population
(CLCFU = 230-172 mL/min) indicating a significant
weakening of the function of kidneys. This observa-
tion may be further confirmed by the diversity in the
biological half-life, which in the our study group
ranged from 1.3 to 5.3 h and in 4 patients of
advanced age it was more than twice higher than the
value reported in subjects with normal renal func-
tion (8-10). Similar observations were made in 44
patients at the age of 44ñ96 years treated with
ciprofloxacin at a dose of 200 mg every 12 h as a
constant rate infusion over 0.5 h (43).
Pharmacokinetic-pharmacodynamic (PK/PD)
indices were used to predict the efficacy of treat-
ment and to optimize the dosage of the antibiotic. To
this end, the pharmacokinetic study results were
combined with the microbiological data. The PK/PD
parameter of cephalosporins is the time at which the
concentration of antibiotic is greater than the MIC of
micro-organism (f∑TC > MIC) and it is often
expressed as a percentage of the dosing interval. It is
recommended that the optimum value of this time
for cephalosporins in patients with infections should
be at least 70% of the dosing interval (11-20).
Microbiological analysis revealed that in stud-
ied patients, isolates were represented by 4 Gram-
positive and 2 Gram-negative strains. Gram-positive
pathogens were S. aureus and S. pneumoniae, while
H. influenza and M. catharralis were identified
Gram-negative pathogens. The MIC of CFU for sen-
sitive isolates ranged from 1 to 2 µg/mL (mean 1.5
µg/mL) and from 1 to 4 µg/mL (mean 2.5 µg/mL),
respectively, for Gram-positive and Gram-negative
strains (for details, see Table 6). The analysis of the
obtained values of f∑TC>MIC indicated that in the
case of only two younger patients CFU dosage
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(1500 mg iv every 8 h) for infections of S. aureus
(MIC = 1 µg/mL) and S. pneumoniae (MIC = 1
µg/mL) assured effectiveness of the treatment as the
value of this time is optimal and amounted to 99.3%
(7.95 h) and 98.9% (7.91 h) of the dosing interval. In
the case of four patients infected with M. catarrhalis
(MIC = 1 µg/mL), S. pneumonia (MIC = 2 µg/mL),
H. influenzae (MIC = 4 µg/mL), and S. aureus (MIC
= 2 µg/mL), who were treated with a dose of 1500
mg CFU every 8 h, free CFU concentrations in
serum of these patients significantly exceeded
determined MICs and maintained above the MIC
values for 14 ñ 25.6 h. Such large values of f∑TC >
MIC in these patients suggest that a reduction of the
dose used or dosing interval prolongation is
required. The latter solution seems to be more con-
venient for both the patient and the medical staff.
The correctness of new dosing intervals proposed
based on Eq. 2 were further confirmed by comput-
er simulations. Stimulations of unbound CFU con-
centrations indicated that two patients with moder-
ate renal impairment (CLcr = 40-50 mL/min)
should be treated with CFU given at a dose of 1500
mg iv every 12 hours. In turn, in two patients with
severe renal failure (CLcr = 30-37 mL/min), the
dose of 1500 mg iv CFU every 24 h was recom-
mended. Based on the simulations performed (Fig.
4) it seems that CFU dosage of 1500 mg and
extended dosing interval (12 h or 24 h) ensure opti-
mal PK/PD parameters values with respect to the
pathogens that cause infections, reducing the risk of
toxicity and costs of treatment. 
CONCLUSION
In this report, an assay for measuring the con-
centrations of CFU in low-volume serum samples is
described. This method appears to be suitable for
use in the clinical laboratory for CFU monitoring
and PK/PD based dosage adjustment. It can be rou-
tinely used in clinical diagnostic laboratories where
a basic HPLC/UV system is available. The method
is fast, simple, reliable, and reproducible. The lower
limits of quantification allow the measurement of
CFU concentrations in serum down to the MIC val-
ues reported for most relevant Gram-negative
pathogens. The large differences in pharmacokinet-
ic parameters observed in the studied patients indi-
cate a need to consider both pharmacokinetic and
pharmacodynamic criteria during antibiotic therapy.
The presented approach can be useful for optimizing
antimicrobial therapy with CFU leading to an
increased efficacy and safety and thus, contributing
to the cost savings of treatment with this antibiotic.
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